The Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) by eight companies/universities/institutes. The top development phase for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) is preclinical with five drugs in that stage. The Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) pipeline products market are: Takeda Pharmaceutical, TagCyx Biotechnologies and GC Biopharma.

The key targets in the Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) pipeline products market include A Disintegrin And Metalloproteinase With Thrombospondin Motifs 13 (Von Willebrand Factor Cleaving Protease or ADAMTS13 or EC 3.4.24.87), Von Willebrand Factor (VWF), and Plasminogen (Plasmin or PLG or EC 3.4.21.7).

The key mechanisms of action in the Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) pipeline product include Von Willebrand Factor (VWF) Inhibitor with two drugs in Preclinical. The Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) pipeline products include one routes of administration with the top ROA being Intravenous and seven key molecule types in the Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) pipeline products market including Recombinant Enzyme, and Recombinant Protein.

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) overview

Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, rapid heart rate, shortness of breath, speech changes, weakness, and yellowish color to the skin (jaundice). Treatment includes surgery to remove the spleen and drugs that suppress the immune system, such as corticosteroids.

For a complete picture of Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.